News – Page 1084 – Endpoints News

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

8 years ago

Ex-Eli Lilly exec Azar lands HHS nomination as Trump champions lower drug prices

8 years ago

Alnylam's patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac

8 years ago

Novartis spotlights its top 4 blockbuster late-stage pipeline projects

8 years ago

Novartis co-opts Homology's gene-editing tech for R&D pipeline

8 years ago

Bill Gates has a $100M and a 5-point strategy to end 15 years of failure in Alzheimer’s R&D

8 years ago

Nektar takes the spotlight at SITC touting some promising early data for hard-to-treat cancers

8 years ago

Juno uses lethal neurotox lessons to guide Goldilocks formula for its next-gen CAR-T

8 years ago

J&J antes $50M to get Zymeworks' 6th big bispecifics alliance underway, with $6B in total milestones on the table

8 years ago

An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem

8 years ago

Novartis makes its case on why RTH258 can grab a blockbuster piece of Regeneron's AMD market

8 years ago

Sangamo joins biotech migration to Oyster Point with new HQ

8 years ago

Celgene's Michael Pehl leaps up to lead role at Immunomedics; GSK nabs Hal Barron to helm R&D; Aimmune CEO to step ...

8 years ago

Roche gets EMA recommendation for Ocrevus; Anthem now covers Sarepta's exon-skipping Duchenne MD drug

8 years ago

Grail vet Bajaj aims for some broad influence with Foresite bucks

8 years ago

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

8 years ago

Aiming for more copycats of each branded drug, FDA expands generic drug priority reviews

8 years ago

With relocation vote looming, the EMA is openly fretting as cities jockey for attention

8 years ago

Dynavax caps a long-running regulatory saga with an FDA OK for hep B vaccine Heplisav

8 years ago

Gottlieb: 'End the shenanigans' on slow-playing REMS to delay generic drug competition

8 years ago

Watch out Merck: Heron snagged FDA approval on Emend competitor

8 years ago

Inching closer to blockbuster status, Seattle Genetics gets fourth FDA win for Adcetris

8 years ago

Mary Szela resigns as CEO of Novelion; China is proving to be a rewarding market for AstraZeneca

8 years ago

Ex-Shire exec Phil Vickers joins the migration to startups, taking the reins at an immuno-oncology biotech

8 years ago

First page Previous page 1081 1082 108310841085 1086 1087 Next page Last page